Carboxyamidotriazole in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

Ovarian Cancer Clinical Trial

Official title:

A Phase II Trial of Orally Administered CAI for Patients With Persistent or Refractory Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00019461
• Other study ID #: CDR0000066216
• Secondary ID: NCI-98-C-0012NCI
• Status: Completed
• Phase: Phase 2
• First received: July 11, 2001
• Last updated: June 19, 2013
• Start date: April 1998
• Est. completion date: October 2007

Study information

• Verified date: June 2003
• Source: National Cancer Institute (NCI)
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Federal Government
• Study type: Interventional

Clinical Trial Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: Phase II trial to study the effectiveness of carboxyamidotriazole in treating patients with refractory or recurrent ovarian epithelial, fallopian tube, or primary peritoneal cancer.

Description:

OBJECTIVES:

• Determine the clinical outcome in patients with ovarian epithelial, fallopian tube, or primary peritoneal cancer treated with carboxyamidotriazole.

OUTLINE: Patients receive oral carboxyamidotriazole daily beginning on day 1. Treatment continues in the absence of disease progression or unacceptable toxicity.

PROJECTED ACCRUAL: A total of 19-40 patients will be accrued for this study within 2 years.

Other known NCT identifiers

• NCT00001682

Recruitment information / eligibility

• Status: Completed
• Enrollment: 0
• Est. completion date: October 2007
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

DISEASE CHARACTERISTICS:

• Histologically confirmed refractory or recurrent ovarian epithelial, fallopian tube, or primary peritoneal cancer

• Measurable disease by physical exam, radiography, peritoneoscopy, or laparoscopy

• No more than 4 weeks since prior peritoneoscopy

• No brain metastases

PATIENT CHARACTERISTICS:

Age:

• 18 and over

Performance status:

• ECOG 0-2

Life expectancy:

• At least 4 months

Hematopoietic:

• Absolute neutrophil count at least 1,000/mm^3

• Platelet count at least 100,000/mm^3

• Hemoglobin at least 9.0 g/dL AND/OR

• Hematocrit at least 27%

Hepatic:

• SGOT/SGPT no greater than 3 times upper limit of normal

• Bilirubin normal

Renal:

• Creatinine no greater than 1.5 mg/dL OR

• Creatinine clearance at least 50 mL/min

Cardiovascular:

• No history of symptomatic cardiac dysrhythmias requiring medication

• At least 6 months since prior myocardial infarction

• No unstable or newly diagnosed angina

Pulmonary:

• No obstructive lung disease requiring oxygen therapy

Other:

• Not pregnant or nursing

• HIV negative

• Must be able to take oral medication

• No concurrent medical condition (e.g., impending bowel obstruction)

• No grade 2 or greater residual peripheral neuropathy

• No active infection

• No other prior or concurrent invasive malignancy within the past 5 years

• No history of acute visual loss other than that associated with retinal detachment

PRIOR CONCURRENT THERAPY:

Biologic therapy:

• At least 4 weeks since prior cytokine therapy

• No concurrent cytokine therapy to maintain WBC count

Chemotherapy:

• At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas, carboplatin, or mitomycin)

• No other concurrent chemotherapy

Endocrine therapy:

• At least 4 weeks since prior hormonal therapy

• No concurrent corticosteroids at doses greater than physiological replacement doses

• No concurrent hormonal therapy

Radiotherapy:

• At least 4 weeks since prior radiotherapy

• No concurrent radiotherapy

Surgery:

• See Disease Characteristics

Other:

• No more than 3 prior treatment regimens

• At least 1 week since prior systemic antibiotics for infection

• No chronic antifungal treatment with antimycotic imidazoles

• No concurrent alternative therapies

Study Design

Primary Purpose: Treatment

Related Conditions & MeSH terms

• Fallopian Tube Cancer
• Fallopian Tube Neoplasms
• Ovarian Cancer
• Ovarian Neoplasms
• Peritoneal Neoplasms
• Primary Peritoneal Cavity Cancer

Intervention

Drug:
• carboxyamidotriazole

• chemotherapy

Locations

Country	Name	City	State
United States	Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support	Bethesda	Maryland

Sponsors (1)

Lead Sponsor	Collaborator
National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

References & Publications (1)

Hussain MM, Kotz H, Minasian L, Premkumar A, Sarosy G, Reed E, Zhai S, Steinberg SM, Raggio M, Oliver VK, Figg WD, Kohn EC. Phase II trial of carboxyamidotriazole in patients with relapsed epithelial ovarian cancer. J Clin Oncol. 2003 Dec 1;21(23):4356-63 — View Citation